Biotechnology company Enhanced Genomics has received new investment in its Series A programme, the company has announced.  Enhanced Genomics, known for pioneering 3D multi-omics to rapidly identify high-confidence, genetically-validated drug targets for common diseases, has received $19 million (£14 million) from BGF, Parkwalk and Meltwind. The funding will be used to expand the company’s internal therapeutic pipeline […]